Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x
height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's
Disease) reduced at least 75%.